PHASE 3 Study Drug May Help Manage Tardive Dyskinesia
The Segal Institute is excited to participate in an important research study of a phase III drug that may help manage Tardive Dyskinesia (TD). By participating in this research, we may help bring much-needed new treatments to our patients living with TD. Made up of nine sites throughout South Florida and South Carolina, the Segal …
